Biogen's Salanersen Shows Motor Milestones in SMA Patients After Gene Therapy
Event summary
- Biogen presented Phase 1b data showing salanersen achieved new motor milestones in 12 of 24 children with SMA previously treated with gene therapy.
- The study demonstrated a 75% reduction in neurofilament light chain (NfL) levels, indicating slowed neurodegeneration.
- Biogen initiated Phase 3 trials for salanersen, including STELLAR-1, STELLAR-2, and SOLAR, with the first study already screening participants.
- Salanersen, an antisense oligonucleotide, is designed for once-yearly dosing and licensed from Ionis Pharmaceuticals.
The big picture
Biogen's Phase 1b data for salanersen highlights the potential for improved outcomes in SMA patients who had suboptimal responses to gene therapy. The initiation of Phase 3 trials positions Biogen to compete in a rapidly evolving SMA treatment market, where innovative therapies are expanding beyond early intervention to address broader patient needs. The focus on once-yearly dosing could offer a significant advantage in patient compliance and market differentiation.
What we're watching
- Therapeutic Efficacy
- Whether salanersen can sustain motor function improvements in broader SMA populations beyond the Phase 1b cohort.
- Clinical Development
- The pace at which Biogen can enroll and generate data from the Phase 3 STELLAR and SOLAR trials.
- Market Positioning
- How salanersen's once-yearly dosing could differentiate it in the competitive SMA treatment landscape.
Related topics